Mayumi Fujita

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 18

Top Topics

Top Venues

Journal of immunology (Baltimore, Md. : 1950)

Pharmaceuticals (Basel, Switzerland)

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Zachary L Z Hay, Dale D Kim, Jennifer M Cimons, Jennifer R Knapp, M Eric Kohler, Mary Quansah, Tiffany M Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang, Brian P O'Connor, Jill E Slansky
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 212 (8) (2024)
Zachary L Z Hay, Dale D Kim, Jennifer M Cimons, Jennifer R Knapp, M Eric Kohler, Mary Quansah, Tiffany M Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang, Brian P O'Connor, Jill E Slansky
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 212 (8) (2024)
Zachary L Z Hay, Dale D Kim, Jennifer M Cimons, Jennifer R Knapp, M Eric Kohler, Mary Quansah, Tiffany M Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang, Brian P O'Connor, Jill E Slansky
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) (2024)
Zachary L Z Hay, Dale D Kim, Jennifer M Cimons, Jennifer R Knapp, M Eric Kohler, Mary Quansah, Tiffany M Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang, Brian P O'Connor, Jill E Slansky
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 212 (8) (2024)
Zili Zhai, Takeshi Yamauchi, Sarah Shangraw, Vincent Hou, Akiko Matsumoto, Mayumi Fujita
Ethanol Metabolism and Melanoma. Cancers 15 (4) (2023)
Zili Zhai, Takeshi Yamauchi, Sarah Shangraw, Vincent Hou, Akiko Matsumoto, Mayumi Fujita
Ethanol Metabolism and Melanoma. Cancers 15 (4) (2023)
Zili Zhai, Takeshi Yamauchi, Sarah Shangraw, Vincent Hou, Akiko Matsumoto, Mayumi Fujita
Ethanol Metabolism and Melanoma. Cancers 15 (4) (2023)
Takeshi Yamauchi, Sarah Shangraw, Zili Zhai, Dinoop R Menon, Nisha Batta, Robert P Dellavalle, Mayumi Fujita
Alcohol as a Non-UV Social-Environmental Risk Factor for Melanoma. Cancers 14 (20) (2022)
Douglas Grant Osborne, Joanne Domenico, Mayumi Fujita
Expression of IL-37 Induces a Regulatory T-Cell-like Phenotype and Function in Jurkat Cells. Cells 11 (16) (2022)
Shilpa Bhatia, Diemmy Nguyen, Laurel B Darragh, Benjamin Van Court, Jaspreet Sharma, Michael William Knitz, Miles Piper, Sanjana Bukkapatnam, Jacob Gadwa, Thomas E Bickett, Shiv Bhuvane, Sophia Corbo, Brian Wu, Yichien Lee, Mayumi Fujita, Molishree Joshi, Lynn E Heasley, Robert L Ferris, Olga Rodriguez, Christopher Albanese, Mohit Kapoor, Elena B Pasquale, Sana D Karam
EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nature communications 13 (1) (2022)
Dinoop R Menon, Yang Li, Takeshi Yamauchi, Douglas Grant Osborne, Prasanna Kumar Vaddi, Michael F Wempe, Zili Zhai, Mayumi Fujita
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals (Basel, Switzerland) 14 (11) (2021)
Isak W Tengesdal, Dinoop R Menon, Douglas Grant Osborne, Charles P Neff, Nicholas E Powers, Fabia Gamboni, Adolfo Gabriele Mauro, Angelo D'Alessandro, Davide Stefanoni, Morkos A Henen, Taylor S Mills, Dennis M De Graaf, Tania Azam, Beat Vogeli, Brent E Palmer, Eric M Pietras, James DeGregori, Aik-Choon Tan, Leo A B Joosten, Mayumi Fujita, Charles A Dinarello, Carlo Marchetti
Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proceedings of the National Academy of Sciences of the United States of America 118 (10) (2021)
Kelsey W Nassar, Jennifer D Hintzsche, Stacey M Bagby, Veronica Espinoza, Christophe Langouët-Astrié, Carol M Amato, Tugs-Saikhan Chimed, Mayumi Fujita, William Robinson, Aik Choon Tan, Rebecca E Schweppe
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Molecular cancer therapeutics 20 (10) (2021)
Dennis M De Graaf, Martin Jaeger, Inge Christina Lamberta van den Munckhof, Rob Ter Horst, Kiki Schraa, Jelle Zwaag, Matthijs Kox, Mayumi Fujita, Takeshi Yamauchi, Laura Mercurio, Stefania Madonna, Joseph Henricus Wilhelmus Rutten, Jacqueline de Graaf, Niels P Riksen, Frank L van de Veerdonk, Mihai M Netea, Leo A B Joosten, Charles A Dinarello
Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. European journal of immunology 51 (3) (2020)
Zili Zhai, Jenny Mae Samson, Takeshi Yamauchi, Prasanna K Vaddi, Yuko Matsumoto, Charles A Dinarello, Dinoop Ravindran Menon, Mayumi Fujita
Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers 12 (9) (2020)
Nabanita Mukherjee, Carol M Amato, Jenette Skees, Kaleb J Todd, Karoline A Lambert, William A Robinson, Robert Van Gulick, Ryan M Weight, Chiara R Dart, Richard P Tobin, Martin D McCarter, Mayumi Fujita, David A Norris, Yiqun G Shellman
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers 12 (8) (2020)
Nabanita Mukherjee, Jenette Skees, Kaleb J Todd, Drake A West, Karoline A Lambert, William A Robinson, Carol M Amato, Kasey L Couts, Robert Van Gulick, Morgan MacBeth, Kelsey Nassar, Aik-Choon Tan, Zili Zhai, Mayumi Fujita, Stacey M Bagby, Chiara R Dart, James R Lambert, David A Norris, Yiqun G Shellman
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell death & disease 11 (6) (2020)
Zili Zhai, Prasanna K Vaddi, Jenny Mae Samson, Tomoya Takegami, Mayumi Fujita
NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Pharmaceuticals (Basel, Switzerland) 14 (1) (2020)